Author:
Shire Norah J.,Sherman Kenneth E.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Troisi CL, Hollinger FB, Hoots WK, et al.: A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993, 81:412–418.
2. Aach RD, Szmuness W, Mosley JW, et al.: Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med 1981, 304:989–994.
3. Goedert JJ, Eyster ME, Lederman MM, et al.: End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002, 100:1584–1589. This study followed over 1800 HCV-infected hemophiliacs for 16 years to examine the associations between age, HBV coinfection, and HIV coinfection on the risk of HCV-related ESLD. Nearly 60% of subjects were coinfected with HIV, and HIV was associated with a significantly increased risk of HCV-related ESLD.
4. Goedert JJ, Brown DL, Hoots K, Sherman KE: Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia 2004, 10(suppl 4):205–210. The authors examine the prevalence and consequences of viral hepatitis and HIV in hemophiliacs in the post-HAART era. In the years 2001 to 2003, nearly 30% of hemophiliacs were coinfected with HCV and HIV, and approximately 5% with HCV and HBV. Liver-related morbidity and mortality remain a significant concern in this population.
5. Soucie JM, Nuss R, Evatt B, et al.: Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000, 96:437–442.